A

little-known drug company announced modestly encouraging results for its experimental Alzheimer’s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.

A mid-stage study by a tiny company wouldn’t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug — derived from a bushy, hermaphroditic sea creature — takes a novel approach.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Whether bryostatin-1 is successful in treating Alzheimers, the jury is still out. Maybe it will maybe it will not. Right now it is my informed belief that Anavex 2-73 is the front runner, a potential disease modifier, safe and more effective than the current standard of care.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.